Navigation Links
Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Date:6/1/2011

SAN DIEGO, June 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Jefferies 2011 Global Healthcare Conference on June 8, 2011 at 11:00 a.m. Eastern Time at The Grand Hyatt in New York City.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and plans to commercialize DIFICID™ (fidaxomicin) tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). CDAD is associated with a bacterial infection that is estimated to affect 700,000 people each year in the U.S. alone, and has surpassed MRSA as the leading cause of healthcare-acquired infections in community hospitals. Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
John D. Prunty, Chief Financial Officer & VP Finance
858-90
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
2. Optimer Pharmaceuticals Expands Senior Management Team
3. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
4. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
5. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
6. Trading Halted Today in Optimer Pharmaceuticals Stock
7. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
8. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
9. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
10. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced the ... - November 19-20, 2015)" conference to their offering. ... industry case studies, regulatory updates, latest therapies and technology ... Steven Nichols , OINP Specialist Consultant and Mike ... participating include: - Aptar Pharma ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the ... - November 16-18, 2015)" conference to their offering. Regulatory ... including Columbia, Peru , Brazil , ... Uruguay , Paraguay , Venezuela ... Chile This seminar can be viewed ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each ... among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and ... year, that process led the magazine to tap the National League for Nursing’s ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Symposium (WFS), cosponsored by the Military Officers Association of America (MOAA) and ... "Our Nation's Military: Caring For Our Own,” expert panelists will lead interactive ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... (blinatumomab) – in the news recently following a decision by the Centers for ... – is likely to average approximately $71,000 or roughly 40% of its headline-grabbing ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... pregnant, but visiting a behavioural therapist for a few ... ,Emory University gynaecologist Sarah Berga examined the value ... had stopped ovulating. ,When presenting her findings ... study of 16 women was small and that a ...
... this year in Assam, state Health Minister Himanta Biswa Sarma ... cut motions in the state assembly, Sarma said the exact ... not reached the state capital., ,Admitting that last year ... per cent of the affected area has been covered., ...
... affairs, China today nominated Hong Kong's Margaret Chan to ... Organisation (WHO).// ,Chan currently serves as WHO ... Director- General will be in November this year., ... Jong-wook from South Korea in May this year., ...
... to be infected with a strain of bird flu that may ... Ministry official// Yukol Limlaemthong on Monday. ,Yukol said, "There ... the area has had outbreaks before." ,Officials have ... was in the northern province of Pichit. This was one of ...
... on the heels of banning illegal organ transplants, China ... panacea for a range of blood disorders. ... Ministry of Health said that the sources of peripheral ... registered sources that can be traced., ,The regulations ...
... China's health insurance companies will offer a special policy for ... policy will be available from August 8 after the insurance ... ,It will be valid for 30 days and ... cost 88 yuan ($11) and compensation will include 10,000 yuan ...
Cached Medicine News:Health News:Stress Therapy can Restore Fertility: Study 2
Store microscope slides with ease, speed, efficiency....
... drawers for just about everything imaginable that might ... Each box is designed for long term storage ... of wood over metal systems is overlooked, while ... subtle kind of desiccator and insulator, providing an ...
A prepared Microscope Slide Cataloging and Storage System....
... resistant, plastic covered corrugated boxes interlock ... up to 500 lbs of overhead ... accommodates 2000 slides or 500 tissue ... requirements. Come unassembled boxes require minimal ...
Medicine Products: